Inflammatory intestinal diseases · 2026
Management of Ulcerative Colitis after Mesalamine-Induced Myocarditis: Successful Treatment with Upadacitinib - A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Taro, Nakashima Takatoshi, Kinugasa Mitsuo
Аннотация
INTRODUCTION: Mesalamine intolerance occurs in 5-10% of patients with ulcerative colitis (UC), while myocarditis is an extremely rare but potentially fatal complication. Optimal UC management after mesalamine-induced myocarditis remains unclear.
CASE PRESENTATION: A man in his 30s with left-sided UC developed mesalamine-induced myocarditis 3 weeks after treatment initiation, confirmed by elevated troponin T, reduced ejection fraction (23%), and a positive drug-induced lymphocyte stimulation test. Cardiac function improved with corticosteroids; however, UC relapsed during steroid tapering. After multidisciplinary discussion and shared decision-making, upadacitinib was selected considering potential cardiac risk with anti-TNF therapy and the need to minimize corticosteroid exposure. Rapid clinical improvement was observed, and complete mucosal healing (Mayo endoscopic subscore 0) was confirmed at 6-month follow-up colonoscopy.
CONCLUSION: This is the first reported case of UC complicated by mesalamine-induced myocarditis successfully treated with upadacitinib. Janus kinase inhibitors may represent a therapeutic option when conventional biologics are unsuitable in patients with severe mesalamine intolerance.
CASE PRESENTATION: A man in his 30s with left-sided UC developed mesalamine-induced myocarditis 3 weeks after treatment initiation, confirmed by elevated troponin T, reduced ejection fraction (23%), and a positive drug-induced lymphocyte stimulation test. Cardiac function improved with corticosteroids; however, UC relapsed during steroid tapering. After multidisciplinary discussion and shared decision-making, upadacitinib was selected considering potential cardiac risk with anti-TNF therapy and the need to minimize corticosteroid exposure. Rapid clinical improvement was observed, and complete mucosal healing (Mayo endoscopic subscore 0) was confirmed at 6-month follow-up colonoscopy.
CONCLUSION: This is the first reported case of UC complicated by mesalamine-induced myocarditis successfully treated with upadacitinib. Janus kinase inhibitors may represent a therapeutic option when conventional biologics are unsuitable in patients with severe mesalamine intolerance.